{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Nasal cavity/paranasal reactions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"ANC/AGC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pain: pleural"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Platelets"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Adverse events reported here were at least possibly related to the protocol therapy.","groups":[{"description":"VELCADE given by intravenous push at 1.3 mg/m\\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.\n\nCyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.\n\nChloroquine given at 500 mg orally daily on days 1-14 and 22-35.\n\nEach cycle is 42 days in length.","id":"OG000","title":"Velcade+Cyclophosphamide+Chloroquine"}],"paramType":"NUMBER","populationDescription":"Any patients who started the treatment","reportingStatus":"POSTED","timeFrame":"Treatment period plus 30 days post-treatment","title":"Number of Participants With Adverse Events of Grade 3 or Higher","type":"SECONDARY","unitOfMeasure":"participants"}